EUVIMEDEUVIMED entdecken
Crossref

Tankyrase1/2 inhibitor XAV-939 reverts EMT and suggests that PARylation partially regulates aerobic activities in human hepatocytes and HepG2 cells

Kristof De Vos, Adamantios Mavrogiannis, Justina Clarinda Wolters, Susan Schlenner, Keimpe Wierda, Álvaro Cortés Calabuig, Reena Chinnaraj, Vera Dermesrobian, Yeghig Armoudjian, Maarten Jacquemyn, Nikky Corthout, Dirk Daelemans und 1 weitere

Biochemical Pharmacology · 2024

DOI: 10.1016/j.bcp.2024.116445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Kristof De Vos und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium. Hauptthemen laut MEDLINE: Tankyrases, Hepatocytes, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 124 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The maintenance of a highly functional metabolic epithelium in vitro is challenging. Metabolic impairments in primary human hepatocytes (PHHs) over time is primarily due to epithelial-to-mesenchymal transitioning (EMT). The immature hepatoma cell line HepG2 was used as an in vitro model to explore strategies for enhancing the hepatic phenotype. The phenotypic characterization includes measuring the urea cycle, lipid storage, tricarboxylic acid-related metabolites, reactive oxygen species, endoplasmic reticulum calcium efflux, mitochondrial membrane potentials, oxygen consumptions rate, and CYP450 biotransformation capacity. Expression studies were performed with transcriptomics, co-immunoprecipitation and proteomics. CRISPR/Cas9 was also employed to genetically engineer HepG2 cells. After confirming that PHHs develop an EMT phenotype, expression of tankyrase1/2 was found to increase over time. EMT was reverted when blocking tankyrases1/2-dependent poly-ADP-ribosylation (PARylation) activity, by biochemical and genetic perturbation. Wnt/β-catenin inhibitor XAV-939 blocks tankyrase1/2 and treatment elevated several oxygen-consuming reactions (electron-transport chain, OXHPOS, CYP450 mono-oxidase activity, phase I/II xenobiotic biotransformation, and prandial turnover), suggesting that cell metabolism was enhanced. Glutathione-dependent redox homeostasis was also significantly improved in the XAV-939 condition. Oxygen consumption rate and proteomics experiments in tankyrase1/2 double knockout HepG2 cells then uncovered PARylation as master regulator of aerobic-dependent cell respiration. Furthermore, novel tankyrase1/2-dependent PARylation targets, including mitochondrial DLST, and OGDH, were revealed. This work exposed a new mechanistic framework by linking PARylation to respiration and metabolism, thereby broadening the current understanding that underlies these vital processes. XAV-939 poses an immediate and straightforward strategy to improve aerobic activities, and metabolism, in (immature) cell cultures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TankyrasesHepatocytesEpithelial-Mesenchymal TransitionHumansHep G2 CellsPoly ADP RibosylationEnzyme InhibitorsPhenanthrenes

Stichwörter der Autor:innen

CYP450 biotransformationMitochondrial functionPoly-ADP-ribosylationSandwich-cultured human hepatocytesTankyrase1/2XAV-939

Substanzen

TankyrasesTNKS2 protein, humanTNKS protein, humanEnzyme InhibitorsPhenanthrenes

Autor:innen und Institutionen

  • Laboratory of Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
  • Adaptive Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.
  • Section Systems Medicine of Metabolism and Signaling, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen 9713 AV, the Netherlands.
  • VIB-KU Leuven Center for Brain & Disease Research, 3000 Leuven, Belgium; Electrophysiology Unit, VIB-KU Leuven Center for Brain & Disease Research, 3000 Leuven, Belgium.
  • KU Leuven Genomics Core, Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.
  • KU Leuven Flow and Mass Cytometry Facility, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.

Zitieren

APA

De Vos, K., Mavrogiannis, A., Wolters, J. C., Schlenner, S., Wierda, K., Cortés Calabuig, Á., Chinnaraj, R., Dermesrobian, V., Armoudjian, Y., Jacquemyn, M., Corthout, N., Daelemans, D., & Annaert, P. (2024). Tankyrase1/2 inhibitor XAV-939 reverts EMT and suggests that PARylation partially regulates aerobic activities in human hepatocytes and HepG2 cells. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116445

Vancouver

De Vos K, Mavrogiannis A, Wolters JC, Schlenner S, Wierda K, Cortés Calabuig Á, et al. Tankyrase1/2 inhibitor XAV-939 reverts EMT and suggests that PARylation partially regulates aerobic activities in human hepatocytes and HepG2 cells. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116445

BibTeX
@article{DeVos2024,
  author = {De Vos, Kristof and Mavrogiannis, Adamantios and Wolters, Justina Clarinda and Schlenner, Susan and Wierda, Keimpe and Cortés Calabuig, Álvaro and Chinnaraj, Reena and Dermesrobian, Vera and Armoudjian, Yeghig and Jacquemyn, Maarten and Corthout, Nikky and Daelemans, Dirk and Annaert, Pieter},
  title = {Tankyrase1/2 inhibitor XAV-939 reverts EMT and suggests that PARylation partially regulates aerobic activities in human hepatocytes and HepG2 cells},
  journal = {Biochemical Pharmacology},
  year = {2024},
  doi = {10.1016/j.bcp.2024.116445}
}
Kostenlos starten →